Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference
24 November 2021 - 8:05AM
Business Wire
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage
biotechnology company developing a novel class of virus-like drug
conjugate (VDC) therapies for multiple oncology indications
including ocular and urologic cancers, today announced that
Elisabet de los Pinos, Chief Executive Officer of Aura, will
participate in a fireside chat at the 4th Annual Evercore ISI
HealthCONx conference taking place on Tuesday, November 30, 2021 at
2:15 p.m. Eastern Time.
A live webcast of the fireside chat will be available on the
“Investors & Media” page under the “Events & Presentations”
section of the Company’s website at
https://ir.aurabiosciences.com/events-and-presentations, where a
replay of the webcast will be archived for 90 days following the
presentation date.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company
developing a novel class of virus-like drug conjugate (VDC)
therapies for multiple oncology indications including ocular and
urologic cancers. Aura’s technology utilizes VDCs to target and
destroy cancer cells selectively while activating the immune system
to create long lasting anti-tumor immunity. The company has the
goal of developing this technology in multiple cancer indications
with an initial focus in ocular oncology, life-threatening eye
cancers, the majority of which have no approved drugs available for
treatment. Aura’s lead product candidate belzupacap sarotalocan
(AU-011) is currently in Phase 2 development for the first line
treatment of indeterminate lesions and small choroidal melanoma, a
vision- and life-threatening form of eye cancer where standard of
care radioactive treatment leaves patients with major vision loss
and severe comorbidities. AU-011 was well tolerated in a Phase 1b/2
trial, demonstrating a statistically significant growth rate
reduction in patients with prior active growth and high levels of
tumor control with visual acuity preservation in a majority of
patients. We believe these data provide the potential to
introduce a new standard of care in choroidal melanoma and treat
patients with early-identified lesions for whom no treatments are
currently available. Future clinical development for AU-011 is
planned throughout ocular oncology, including in choroidal
metastases where Aura expects to file an IND during the second half
of 2022. The unique mechanism of action of Aura’s HSPG-targeting
VDCs also enables development of AU-011 as a platform broadly
across multiple solid tumors; the first clinical trial of AU-011
outside ocular oncology is planned for the second half of 2022 in
non-muscle invasive bladder cancer, a high unmet medical need where
patients have poor treatment options and tumor progression leads to
cystectomy (bladder removal) and a high risk of metastases.
Future pipeline growth is expected to include additional drug
conjugates for broad oncology applications. Aura is headquartered
in Cambridge, MA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211123006124/en/
Investor and Media: Matthew DeYoung Argot Partners
212-600-1902 | aura@argotpartners.com
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Apr 2023 to Apr 2024